Improvement of diabetes indices of care by a short pharmaceutical care program

Pharmacy World and Science

Volumn 31, Issue 6, 2009, Pages 689-695

  Turnacilar, Mertkan ^a   Sancar, Mesut ^a   Apikoglu Rabus, Sule ^a   Hursitoglu, Mehmet ^b   Izzettin, Fikret Vehbi ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b Vakif Gureba Teaching and Research Hospital   (Turkey)

Author keywords

Blood pressure; Clinical pharmacist; Diabetes; Glycemic control; Pharmaceutical care; Turkey

Indexed keywords

BIGUANIDE DERIVATIVE; GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACEUTICAL CARE; SELF MONITORING; SYSTOLIC BLOOD PRESSURE; TURKEY (REPUBLIC); WEIGHT CONTROL;

BLOOD GLUCOSE; BLOOD PRESSURE; COMMUNITY PHARMACY SERVICES; DELIVERY OF HEALTH CARE, INTEGRATED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHARMACISTS; PROFESSIONAL ROLE; PROGRAM EVALUATION; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TURKEY;

EID: 76749160204     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-009-9333-9     Document Type: Article

References (40)

1. S Matzer L Leiter D Daneman H Gerstein D Lau S Ludwig, et al. 1998 Clinical practice guidelines for the management of diabetes in Canada CMAJ 159 1 29
2. American Diabetes Association: Implications of the diabetes control and complications trial. Diabetes Care 2002; 25: 25-7.
3. H Abuissa DS Bel JH O'Keefe Jr 2005 Strategies to prevent type 2 diabetes Curr Med Res Opin 21 1107 1114 10.1185/030079905X50606 16004680 (Pubitemid 41032702)
4. AV Chobanian GL Bakris HR Black WC Cushman LA Green JL Izzo Jr, et al. 2003 The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report JAMA 289 2560 2572 10.1001/jama.289.19.2560 1:CAS:528:DC%2BD3sXjvFCqtrk%3D 12748199 (Pubitemid 37430158)
5. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-86.
6. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342: 381-9.
7. UK Prospective Diabetes Study (UKPDS) Group: intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-53.
8. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317: 703-13.
10. L Hansson A Zanchetti SG Carruthers B Dahlof D Elmfeldt S Julius, et al. 1998 HOT Study Group: effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial Lancet 351 1755 1762 10.1016/S0140-6736(98)04311-6 1:CAS:528:DyaK1cXksV2qtrY%3D 9635947 (Pubitemid 28269185)
11. AI Adler IM Stratton HA Neil JS Yudkin DR Matthews CA Cull, et al. 2000 Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study BMJ 321 412 419 10.1136/bmj.321.7258.412 1:STN:280:DC%2BD3cvisFWnsw%3D%3D 10938049
12. JA Garção J Cabrita 2002 Evaluation of a pharmaceutical care program for hypertensive patients in rural Portugal J Am Pharm Assoc 42 858 864 10.1331/108658002762063691
13. G Gonzalez-Martin I Joo I Sanchez 2003 Evaluation of the impact of a pharmaceutical care program in children with asthma Patient Educ Couns 49 13 18 10.1016/S0738-3991(02)00027-7 1:STN:280:DC%2BD3s%2FitFamuw%3D%3D 12527148 (Pubitemid 36071304)
14. CP Paulos CE Nygren C Celedon CA Carcama 2005 Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia Ann Pharmacother 39 939 943 10.1345/aph.1E347 15827075 (Pubitemid 40570674)
15. PM Clark T Karagoz S Apikoglu-Rabus FV Izzettin 2007 Effect of pharmacist-led patient education on adherence to tuberculosis treatment Am J Health-Syst Pharm 64 497 506 10.2146/ajhp050543 17322163 (Pubitemid 46339264)
16. EA Coast-Senior BA Kroner CL Kelley LE Trilli 1998 Management of patient with type 2 diabetes by pharmacists in primary care clinics Ann Pharmacother 32 636 641 10.1345/aph.17095 1:STN:280:DyaK1czgsVKlsA%3D%3D 9640480 (Pubitemid 28283846)
17. LA Jaber H Halapi M Fernet S Tummalapalli H Diwakaran 1996 Evaluation of a pharmaceutical care model on diabetes management Ann Pharmacother 30 238 243 1:STN:280:DyaK28vjtVCgsA%3D%3D 8833557 (Pubitemid 126497295)
18. R Berringer MC Shibley CC Cary CB Pugh PA Powers JA Rafi 1999 Outcomes of a community pharmacy-based diabetes monitoring program J Am Pharm Assoc 39 791 797 1:STN:280:DC%2BD3c%2FnslCntg%3D%3D
19. MK Van Veldhuizen-Scott LB Widmer SA Stacy NG Popovich 1995 Developing and implementing a pharmaceutical care model in an ambulatory care setting for patients with diabetes Diabetes Educ 21 117 123 10.1177/014572179502100207 7698064
20. J Wermeille M Bennie I Brown J McKnight 2004 Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team-a pilot study Pharm World Sci 26 18 25 10.1023/B:PHAR. 0000013465.24857.a8 15018255 (Pubitemid 38250176)
21. JP Anaya JO Rivera K Lawson J Garcia J Luna Jr M Ortiz 2008 Evaluation of pharmacist-managed diabetes mellitus under a collaborative drug therapy agreement Am J Health Syst Pharm 65 1841 1845 10.2146/ajhp070568 18796426
22. CM Morello EB Zadvorny MA Cording RT Suemoto J Skog A Harari 2006 Development and clinical outcomes of pharmacist-managed diabetes care clinics Am J Health Syst Pharm 63 1325 1331 10.2146/ajhp050430 16809752 (Pubitemid 44116785)
23. BK Irons CF Seifert NA Horton 2008 Quality of care of a pharmacist-managed diabetes service compared to usual care in an indigent clinic Diabetes Technol Ther 10 220 226 10.1089/dia.2007.0262 1:CAS:528: DC%2BD1cXlvFynsrY%3D 18473697 (Pubitemid 351677588)
24. T Fera BM Bluml WM Ellis CW Schaller DG Garrett 2008 The diabetes ten city challenge: interim clinical and humanistic outcomes of a multi-site community pharmacy diabetes care program J Am Pharm Assoc 48 181 190 10.1331/JAPhA.2008.07166
25. CW Cranor DB Christensen 2003 The Asheville Project: short-term outcomes of a community pharmacy diabetes care program J Am Pharm Assoc 43 149 159 10.1331/108658003321480696
26. CW Cranor BA Bunting DB Christensen 2003 The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program J Am Pharm Assoc 43 173 184 10.1331/108658003321480713
27. ST Cioffi MF Caron JS Kalus P Hill TE Buckley 2004 Glycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic Ann Pharmacother 38 771 775 10.1345/aph.1D359 15031417 (Pubitemid 38509050)
28. HM Choe S Mitrovich D Dubay RA Hayward SL Krein S Vijan 2005 Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial Am J Manag Care 11 253 260 15839185
29. S Suppapitiporn B Chindavijak S Onsanit 2005 Effect of diabetes drug counselling by pharmacist, diabetic disease booklet and special medication containers on glycemic control of type 2 diabetes mellitus: a randomized controlled trial J Med Assoc Thai 88 S134 S141 16623018
30. AD Brooks RS Rihani CL Derus 2007 Pharmacist membership in a medical group's diabetes health management program Am J Health Syst Pharm 64 617 621 10.2146/ajhp060095 17353570 (Pubitemid 46481862)
31. CD Hepler LM Strand 1990 Opportunities and responsibilities in pharmaceutical care Am J Hosp Pharm 47 533 543 1:STN:280:DyaK3c7ps1Sgsw%3D%3D 2316538
32. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the clinician's guide 2nd Edition The McGraw-Hill Companies, Inc. 2004 USA.
33. NR Al-Mazroui MM Kamal NM Ghabash TA Yacout PL Kole JC McElnay 2009 Influence of pharmaceutical care on health outcomes in patients with type 2 diabetes mellitus Br J Clin Pharmacol 67 547 557 10.1111/j.1365-2125.2009.03391. x 1:CAS:528:DC%2BD1MXmtVyru7c%3D 19552750
34. CL Rohlfing HM Wiedmeyer RR Little JD England A Tennill DE Goldstein 2002 Defining the relationship between plasma glucose and HbA1c, analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial Diabetes Care 25 275 278 10.2337/diacare.25.2.275 1:CAS:528:DC%2BD38Xhtlyksrk%3D 11815495 (Pubitemid 41079621)
35. DL McLean FA McAlister JA Johnson KM King MJ Makowsky CA Jones, et al. 2008 SCRIP-HTN Investigators: A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN) Arch Intern Med 24 168 2355 2361 10.1001/archinte.168.21.2355
36. DM Scott ST Boyd M Stephan SC Augustine TP Reardon 2006 Outcomes of pharmacist-managed diabetes care services in a community health center Am J Health Syst Pharm 63 2116 2122 10.2146/ajhp060040 17057049 (Pubitemid 44757783)
37. EM Vivian 2002 Improving blood pressure control in a pharmacists-managed hypertension clinic Pharmacotherapy 22 1533 1540 10.1592/phco.22.17.1533.34127 12495164
38. RA Ahrens M Hower AM Best 2003 Effects of weight reduction interventions by community pharmacists J Am Pharm Assoc 43 583 590 10.1331/154434503322452210
39. AJ Zillich M Ryan A Adams B Yeager K Farris 2003 Effectiveness of a pharmacist-based smoking-cessation program and its impact on quality of life Pharmacotherapy 22 759 765 10.1592/phco.22.9.759.34073
40. RM Clifford WA Davis KT Batty TME Davis 2005 Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes. The Fremantle Diabetes Study Diabetes Care 28 771 776 10.2337/diacare.28.4.771 15793171 (Pubitemid 40434471)